Ina Bisha

AstraZeneca (Germany)

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Philip Martin

University of California Division of Agriculture and Natural Resources

Yashaswi Shrestha

AstraZeneca (United States)

Ronald Herbst

AstraZeneca (United States)

Nabendu Pore

AstraZeneca (United States)

Melanie M. Frigault

AstraZeneca (United States)

Nathan Standifer

Tempest Technologies (United States)

John Meekin

AstraZeneca (United States)

Maria Libera Ascierto

AstraZeneca (United States)

Maria Jure‐Kunkel

Genmab (United States)

Raymond Rothstein

AstraZeneca (Brazil)

Cooperative Institutions

AstraZeneca (United States)

AstraZeneca (Germany)

AstraZeneca (United Kingdom)

AstraZeneca (Brazil)

AREA Science Park

AstraZeneca (Japan)

Scuola Internazionale Superiore di Studi Avanzati

National Cancer Institute

National Institutes of Health

Klinikum rechts der Isar

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Supplementary Figure S5 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown

Nabendu Pore Song Wu Nathan Standifer Maria Jure‐Kunkel Melissa de los Reyes

Characterization of innate and adaptive immune cell recruitment to CT26 STK11 KO tumors compared to CT26 WT. (A) Work flow for single cell RNA (scRNA) analysis of CD45+ cells isolated from CT26 WT and STK11 KO clones. Data analysis including cell quality control and filtering steps used to subset the raw scRNA-seq data into CD45+ cells and the two main immune cell populations subsequently analyzed as described in the Supplementary Appendix. (B) Number of CD45+ immune cells per sample used for downstream analysis. (C) Uniform Manifold Approximation and Projection (UMAP) of CD45+ immune cells colored by major cell populations as determined by Louvain clustering: B cell, monocyte/macrophage/DC (Mono.Macro.DC), neutrophil, T cell/NK cell (T.NK), basophil, and pDC clusters are represented as indicated. (D) UMAP plots showing the expression of key genes used in the identification of immune cell clusters. Ptprc = CD45, immune cell marker; Cd3e = epsilon subunit of CD3 complex, T cell marker; Ncr1 = NKp46, NK cell marker; Csf1r = CSF1 receptor, monocyte/macrophage marker; Csf3r = CSF3 (G-CSF) receptor, neutrophil/gMDSC marker; Siglech, Siglec H, plasmacytoid DC marker; CD19, B cell marker; Mcpt8 = mast cell protease 8, basophil/mast cell marker. (E) Percentage of each cell cluster among CD45+ immune population per sample. (F) Comparison between median percentage of immune cell clusters for CT26 WT and STK11 KO clones as indicated. *p < 0.05, one-way ANOVA. (G) Levels of intratumoral granulocytic (Ly6G+) cells as a fraction of CD45+ immune cells in WT and STK11 KO CT26 tumors as determined by flow cytometry. (H) UMAP representation showing single-cell RNA subclustering of the monocyte/macrophage/DC sub-populations as determined by Louvain clustering. (I) Top highly expressed genes between monocyte/macrophage/DC sub-clusters used for annotation as labeled in K and L. (J) Percentage of monocyte/macrophage/DC sub-populations per sample. (K) Comparison between median percentage of cells that are present in each monocyte/macrophage/DC cluster among CT26 WT and STK11 KO clones. *p < 0.05, one-way ANOVA comparing CT26 STK11 KO clones to CT26 WT. (L) Hierarchical clustering of monocyte/macrophage subpopulations (Mono.Macro) based on M1 and M2 gene signatures, as defined by Orecchioni M, et al (5). Genes were also subjected to hierarchical clustering. (M) Levels of intra-tumoral CD163+ tumor-associated macrophages determined by IHC. (N) CD45neg tumor and non-immune stromal cell RNA levels of chemokines and chemokines associated with recruitment and suppressive function of MDSCs and TAMs and of TMEM173/STING.

10.1158/2159-8290.22540421

Cite

Citations (0)

Supplementary Figure S8 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown

Nabendu Pore Song Wu Nathan Standifer Maria Jure‐Kunkel Melissa de los Reyes

Antitumor efficacy of TNFRSF agonist immunotherapies in CT26 STK11wt or KO mice. Survival of mice engrafted with (A) CT26 WT or (B) CT26 STK11 KO clone 26C16 treated with isotype control antibodies, anti-PD-L1 plus anti-CTLA-4 mAbs or immune agonist Abs anti-OX40, anti-ICOS, or anti-CD137, as indicated.

Durvalumab

Tremelimumab

CD137

clone (Java method)

10.1158/2159-8290.22540412.v1

Cite

Citations (0)

Table 2 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Andrew L. Coveler Matthew J. Reilley Mark M. Zalupski Teresa Macarulla Christos Fountzilas

TEAEs occurring at any severity in ≥20% of patients in any arm in the dose-expansion phase (as-treated population; N = 170).

Durvalumab

Table (database)

10.1158/1078-0432.27231286

Cite

Citations (0)

A Phase 1b/2 Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Clinical Cancer Research (2024)

Andrew L. Coveler Matthew J. Reilley Mark M. Zalupski Teresa Macarulla Christos Fountzilas

Pancreatic ductal adenocarcinoma upregulates CD73, potentially contributing to immune surveillance evasion. Combining oleclumab (CD73 inhibitor) and durvalumab with chemotherapy may identify an effective treatment option.

Durvalumab

10.1158/1078-0432.ccr-24-0499

Cite

Citations (1)

Supplementary Table S2 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown

Nabendu Pore Song Wu Nathan Standifer Maria Jure‐Kunkel Melissa de los Reyes

List of genes differentially expressed in STK11mut vs STK11wt tumors.

Durvalumab

Tremelimumab

STK11

10.1158/2159-8290.22540403

Cite

Citations (0)

The molecular mechanism of secondary sodium symporters elucidated through the lens of the computational microscope

RSC Advances (2016)

Ina Bisha Alessandra Magistrato

Transport of molecules across cellular membranes is a key biological process for normal cell function. In this review we describe current state-of-the-art knowledge on molecular mechanism of secondary active transporters obtained by molecular simulations studies.

10.1039/c5ra22131e

Cite

Citations (15)

Mechanism of Ionic Permeation in the Mimics of CNG Channels: A Structural, Functional and Computational Analysis

Biophysical Journal (2014)

Luisa M. R. Napolitano Ina Bisha Manuel Arcangeletti Arin Marchesi Matteo De March

10.1016/j.bpj.2013.11.4173

Cite

Citations (0)

A Candidate Ion-Retaining State in the Inward-Facing Conformation of Sodium/Galactose Symporter: Clues from Atomistic Simulations

Journal of Chemical Theory and Computation (2013)

Ina Bisha Alessandro Laio Alessandra Magistrato Alejandro Giorgetti Jacopo Sgrignani

The recent Vibrio parahaemolyticus sodium/galactose (vSGLT) symporter crystal structure captures the protein in an inward-facing substrate-bound conformation, with the sodium ion placed, by structural alignment, in a site equivalent to the Na2 site of the leucine transporter (LeuT). A recent study, based on molecular dynamics simulations, showed that the sodium ion spontaneously leaves its initial position diffusing outside vSGLT, toward the intracellular space. This suggested that the crystal structure corresponds to an ion-releasing state of the transporter. Here, using metadynamics, we identified a more stable Na(+) binding site corresponding to a putative ion-retaining state of the transporter. In addition, our simulations, consistently with mutagenesis studies, highlight the importance of D189 that, without being one of the Na(+)-coordinating residues, regulates its binding/release.

Metadynamics

10.1021/ct3008233

Cite

Citations (25)

Supplementary Figure S1 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Andrew L. Coveler Matthew J. Reilley Mark M. Zalupski Teresa Macarulla Christos Fountzilas

Study design: dose-escalation and dose-expansion phases

Durvalumab

Metastatic adenocarcinoma

10.1158/1078-0432.27231325

Cite

Citations (0)